Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: principles (564), values (295)

Atezolizumab1680mg

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf

Atezolizumab

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally advanced/ metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab.pdf

Cisplatin (35) Gemcitabine ver1.1

Description: Chemotherapy Protocol BLADDER CISPLATIN (35)-GEMCITABINE Regimen Bladder-Cisplatin (35)-Gemcitabine Indication For use in patients unable to tolerate standard cisplatin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Cisplatin-35-Gemcitabine-ver1.1.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This protocol was developed in response
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Atezolizumab

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab Regimen • Bladder – Atezolizumab Indication • The treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab.pdf

Tivozanib

Description: Chemotherapy Protocol RENAL CELL Regimen TIVOZANIB • Renal Cell - Tivozanib Indication • Patients with a confirmed histological diagnosis of renal cell carcinoma with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Tivozanib.pdf

InP-MATRix

Description: Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabine-Methotrexate-Rituximab-Thiotepa Indication • Non-Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf

ABVD – Bleomycin-Dacarbazine-Doxorubicin-Vinblastine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-DACARBAZINE-DOXORUBICIN-VINBLASTINE (ABVD) Regimen Lymphoma – ABVD-Bleomycin-Dacarbazine-Doxorubicin-Vinblastine Indication Hodgkin’s Lymphoma Toxicity Drug
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/ABVD-–-Bleomycin-Dacarbazine-Doxorubicin-Vinblastine-Ver-1.2.pdf

InP-PAM-(cycles 5-6) v1

Description: Chemotherapy Protocol Sarcoma DOXORUBICIN-METHOTREXATE (cycles 5-6) Inpatient Regimen There are multiple versions of this protocol in use. Please ensure
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-PAM-cycles-5-6-v1.pdf

MyelomaVCD(SC28)Bortezomib(SC)CyclophosphamideDexamethasone28dayVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-28) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (28 day) Regimen Multiple Myeloma – VCD (SC-28)-Bortezomib (SC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDSC28BortezomibSCCyclophosphamideDexamethasone28dayVer1.pdf

381 to 390 of 427

Previous … 37 38 39 40 41 … Next